Azedra injection – first treatment approved for rare adrenal tumors
The U.S. Food and Drug Administration approved Azedra (iobenguane I 131) injection for intravenous use for the treatment of adults and adolescents age 12 and
The U.S. Food and Drug Administration approved Azedra (iobenguane I 131) injection for intravenous use for the treatment of adults and adolescents age 12 and
Heavy birthweight female babies are twice as likely to develop rheumatoid arthritis in adulthood as their average birthweight peers, suggests research published ahead of print in the Annals of the Rheumatic Diseases.
– People who have a birth weight over 10 pounds are twice as likely to develop rheumatoid arthritis when they are adults compared to individuals born with an average birth weight, according to a study published by researchers from Hospital for Special Surgery online in advance of print in the Annals of the Rheumatic Diseases.